{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=94",
    "query": {
      "intervention": "Safety Control",
      "page": 94
    },
    "page_size": 10
  },
  "pagination": {
    "page": 94,
    "page_size": 10,
    "total_count": 14147,
    "total_pages": 1415,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=95&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=93&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T15:10:49.646Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01090310",
      "title": "Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-infectious Uveitis"
      ],
      "interventions": [
        {
          "name": "AIN457",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2010-08",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2016-01-14",
      "last_synced_at": "2026-11-09T15:10:49.646Z",
      "location_count": 10,
      "location_summary": "Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01090310"
    },
    {
      "nct_id": "NCT03500679",
      "title": "A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ExPEC4V",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2018-05-09",
      "completion_date": "2019-06-11",
      "has_results": true,
      "last_update_posted_date": "2019-11-26",
      "last_synced_at": "2026-11-09T15:10:49.646Z",
      "location_count": 2,
      "location_summary": "Wichita, Kansas • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03500679"
    },
    {
      "nct_id": "NCT07722546",
      "title": "A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graves' Disease"
      ],
      "interventions": [
        {
          "name": "Felzartamab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-07-30",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-09T15:10:49.646Z",
      "location_count": 13,
      "location_summary": "Glendale, Arizona • Los Angeles, California • San Jose, California + 10 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07722546"
    },
    {
      "nct_id": "NCT04365218",
      "title": "A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "MEDI8367",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2020-07-22",
      "completion_date": "2021-01-03",
      "has_results": false,
      "last_update_posted_date": "2022-04-21",
      "last_synced_at": "2026-11-09T15:10:49.646Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04365218"
    },
    {
      "nct_id": "NCT05528510",
      "title": "A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Guselkumab Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Guselkumab Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Guselkumab Dose 3",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 418,
      "start_date": "2022-09-13",
      "completion_date": "2028-10-06",
      "has_results": true,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-09T15:10:49.646Z",
      "location_count": 32,
      "location_summary": "Litchfield Park, Arizona • Apple Valley, California • Lancaster, California + 26 more",
      "locations": [
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Apple Valley",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05528510"
    },
    {
      "nct_id": "NCT04201262",
      "title": "An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Ravulizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 58,
      "start_date": "2019-12-09",
      "completion_date": "2024-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-11-09T15:10:49.646Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04201262"
    },
    {
      "nct_id": "NCT07412288",
      "title": "First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "KT-579",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kymera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2026-02-23",
      "completion_date": "2026-08-22",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-09T15:10:49.646Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07412288"
    },
    {
      "nct_id": "NCT04518462",
      "title": "Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lower Extremity Surgery",
        "Bunion",
        "Metatarsophalangeal Fushion",
        "Midfoot Fusion",
        "Hindfoot Fushion",
        "Total Ankle Arthroplasty"
      ],
      "interventions": [
        {
          "name": "Exparel",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2020-10-20",
      "completion_date": "2021-04-05",
      "has_results": true,
      "last_update_posted_date": "2022-07-18",
      "last_synced_at": "2026-11-09T15:10:49.646Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Pasadena, California • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04518462"
    },
    {
      "nct_id": "NCT04576988",
      "title": "A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Sotatercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Background PAH Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2021-01-25",
      "completion_date": "2022-12-06",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-11-09T15:10:49.646Z",
      "location_count": 39,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04576988"
    },
    {
      "nct_id": "NCT04421027",
      "title": "A Study of Baricitinib (LY3009104) in Participants With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1525,
      "start_date": "2020-06-12",
      "completion_date": "2021-06-10",
      "has_results": true,
      "last_update_posted_date": "2022-07-28",
      "last_synced_at": "2026-11-09T15:10:49.646Z",
      "location_count": 25,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04421027"
    }
  ]
}